<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for recurrent germ cell tumors: Vinblastine, ifosfamide, and &lt;font style="white-space: nowrap;"&gt;cisplatin (VeIP)&lt;sup&gt;[1-3]&lt;/sup&gt;&lt;/font&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for recurrent germ cell tumors: Vinblastine, ifosfamide, and <font style="white-space: nowrap;">cisplatin (VeIP)<sup>[1-3]</sup></font></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for recurrent germ cell tumors: Vinblastine, ifosfamide, and <font style="white-space: nowrap;">cisplatin (VeIP)<sup>[1-3]</sup></font></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 21 days.<br/> <strong>Total cycles:</strong> 4 cycles. </td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Vinblastine</td> <td>0.11 mg/kg per <span style="white-space: nowrap;">day*</span> IV</td> <td>Mix in 50 to 100 mL <span style="white-space: nowrap;">NS<sup>¶</sup></span> and administer over 5 to <span style="white-space: nowrap;">10 minutes.<sup>Δ</sup></span></td> <td>Daily, days 1 and 2</td> </tr> <tr> <td>Cisplatin</td> <td>20 mg/m<sup>2</sup> per day IV</td> <td>Dilute in 250 mL <span style="white-space: nowrap;">NS<sup>¶</sup></span> and administer over 30 to 60 minutes (or at <span style="white-space: nowrap;">1 mg/min)<sup>◊</sup></span> after vinblastine. Do not administer with aluminum needles or sets.</td> <td>Daily, days 1 through 5</td> </tr> <tr> <td><span style="white-space: nowrap;">Mesna<sup>§</sup></span></td> <td>240 mg/m<sup>2</sup> IV bolus prior to each dose of ifosfamide, then 240 mg/m<sup>2</sup> IV bolus at 4 and 8 hours after the start of ifosfamide administration each day (total daily mesna dose of <span style="white-space: nowrap;">720 mg/m<sup>2</sup>).<sup>¥</sup></span></td> <td>Mix in 100 mL NS or <span style="white-space: nowrap;">D5W<sup>¶</sup></span> and administer over 15 minutes. Total concentration of mesna should not exceed <span style="white-space: nowrap;">20 mg/mL.<sup>[4]</sup></span></td> <td>Daily, days 1 through 5</td> </tr> <tr class="divider_bottom"> <td>Ifosfamide</td> <td>1200 mg/m<sup>2</sup> per <span style="white-space: nowrap;">day*</span> IV</td> <td>Mix with NS or <span style="white-space: nowrap;">D5W<sup>¶</sup></span> or sterile water for injection to a final concentration of 0.6 to 20 mg/mL and infuse over 3 hours.</td> <td>Daily, days 1 through 5</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Hydration</strong></td> <td colspan="3"> <ul> <li><strong>Cisplatin:</strong> Induction of diuresis minimizes the risk of cisplatin nephrotoxicity. Hydration with 1 to 2 L of IV fluids is recommended to establish adequate urinary output (&gt;100 mL/hour) for at least 2 hours prior to and 2 hours after cisplatin administration.</li> <li>Alternatively, pretreatment hydration with 1 to 2 L of fluid infused for 8 to 12 hours prior to each dose of <span style="white-space: nowrap;">cisplatin.<sup>[5]</sup></span></li> <li>Refer to UpToDate topics on cisplatin nephrotoxicity.</li> <li><strong>Ifosfamide:</strong> Adequate hydration (at least 2 L of oral or IV fluids per day) should be maintained with ifosfamide to reduce the risk of ifosfamide bladder <span style="white-space: nowrap;">toxicity.<sup>[6]</sup></span></li> <li>Refer to UpToDate topics on chemotherapy and radiation-related hemorrhagic cystitis in cancer patients.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li><strong>HIGH</strong> (&gt;90% frequency of emesis).</li> <li>Concomitant administration of a neurokinin 1 receptor antagonist (eg, aprepitant) may increase the risk of ifosfamide neurotoxicity; it is avoided at many institutions.</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Routine prophylaxis not indicated for cisplatin, ifosfamide, or vinblastine.</li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Vinblastine is a vesicant and can cause significant tissue damage; avoid extravasation.</li> <li>Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is indicated since the incidence of neutropenic fever with this regimen was 39 and 71%, respectively, in two different <span style="white-space: nowrap;">studies.<sup>[1,2]</sup></span></li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>A lower starting dose of vinblastine may be needed in patients with hepatic impairment.</li> <li>A lower starting dose of ifosfamide may be needed for patients with renal or liver impairment.</li> <li>The optimal approach to cisplatin therapy in patients with pre-existing renal impairment is unknown. Patients are typically treated with cisplatin regardless of renal function since treatment intent is curative, but appropriate clinical judgement is necessary.</li> <li>Before starting treatment, it is essential to exclude or correct any urinary tract obstruction.</li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents, and chemotherapy nephrotoxicity and dose modification in patients with kidney impairment, conventional cytotoxic agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Hemorrhagic cystitis prevention</strong></td> <td colspan="3"> <ul> <li>Mesna does not prevent hemorrhagic cystitis in all patients.</li> <li>Perform urinalysis on a morning specimen of urine for hematuria daily during ifosfamide administration. If microscopic hematuria (ie, greater than 10 RBCs per high-power field) is present, then subsequent administration of ifosfamide should be withheld until complete <span style="white-space: nowrap;">resolution.<sup>[6]</sup></span></li> <li>Refer to UpToDate topics on chemotherapy and radiation-related hemorrhagic cystitis in cancer patients.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Neurotoxicity issues</strong></td> <td colspan="3"> <ul> <li>There is an increased risk of encephalopathy for those with prior history of ifosfamide-related encephalopathy, renal dysfunction, low serum albumin, and those with concomitant use of aprepitant or prior cisplatin treatment. Monitor for CNS toxicity and discontinue ifosfamide treatment for encephalopathy.</li> <li>Refer to UpToDate topics on overview of neurologic complications of conventional non-platinum cancer chemotherapy.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Ototoxicity</strong></td> <td colspan="3"> <ul> <li>Incidence of ototoxicity maybe increased when vinblastine is administered with ototoxic agents, including platinum <span style="white-space: nowrap;">agents.<sup>[7]</sup></span> Use caution in patients with prior hearing loss.</li> <li>Refer to UpToDate topics on overview of neurologic complications of platinum-based chemotherapy.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential and platelet count prior to each new treatment cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assess electrolytes (especially potassium, magnesium, and phosphate) and renal function daily during administration and prior to each new treatment cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assess liver function tests daily during administration and prior to each new treatment cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Check urinalysis (or urine dipstick) prior to and during ifosfamide administration to monitor for hemorrhagic cystitis.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for ifosfamide-related neurotoxicity (eg, encephalopathy, coma, rarely seizures, weakness, neuropathy, ataxia, cranial nerve dysfunction) daily. Assess changes in neurologic function, including neuropathy and/or paresthesias, prior to each new treatment cycle.</li> <li>Refer to UpToDate topics on overview of neurologic complications of non-platinum cancer chemotherapy.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for constipation and/or ileus.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelosuppression</strong></td> <td colspan="3"> <ul> <li>For febrile neutropenia, thrombocytopenic bleeding event, or thrombocytopenia requiring transfusion, reduce vinblastine and ifosfamide doses by 25% each for subsequent <span style="white-space: nowrap;">courses.<sup>[1,2]</sup></span></li> <li>Patients with persistent myelosuppression on day 22 may still proceed with the next treatment cycle. Perform daily CBC. Omit the ifosfamide dose on day 5 if the WBC does not rise to &gt;2.5 × 10<sup>3</sup> cells/mm<sup>3</sup> and platelets do not rise to &gt;100 × <span style="white-space: nowrap;">10<sup>6</sup> cells/mm<sup>3</sup>.<sup>[1,2]</sup></span></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Hemorrhagic cystitis</strong></td> <td colspan="3"> <ul> <li>Withhold further ifosfamide doses and continue the daily mesna dose if urinalysis shows 10 or more erythrocytes per high-powered field until hematuria is <span style="white-space: nowrap;">resolved.<sup>[1,2,6]</sup></span></li> <li>Refer to UpToDate topics on chemotherapy and radiation-related hemorrhagic cystitis in cancer patients.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Nephrotoxicity</strong></td> <td colspan="3"> <ul> <li><strong>Cisplatin:</strong> No dose adjustments for cisplatin were provided for this regimen, but the rates of grade 2, 3, and 4 nephrotoxicity were 25, 9, and 6%, <span style="white-space: nowrap;">respectively.<sup>[1]</sup></span> Among those with severe (grade 3 or 4) nephrotoxicity, the rates of irreversible nephrotoxicity were approximately 2% <span style="white-space: nowrap;">each.<sup>[1,2]</sup></span></li> <li>The United States Prescribing Information for cisplatin recommends that the drug be withheld until serum creatinine is &lt;1.5 mg/dL and/or BUN is <span style="white-space: nowrap;">&lt;25 mg/dL.<sup>[5]</sup></span></li> <li>For grade ≥2 nephrotoxicity during treatment (ie, creatinine &gt;1.5 times normal value despite adequate hydration), reduce the dose of cisplatin if CrCl determined prior to the next cycle is &lt;60 mL/min.</li> <li><strong>Ifosfamide:</strong> Reduce the ifosfamide dose by 25% for a serum creatinine <span style="white-space: nowrap;">≥2 mg/dL.<sup>[1,2]</sup></span></li> <li>Ifosfamide is associated with cumulative nephrotoxicity and electrolyte abnormalities, mostly at a total dose above 60 g/m<sup>2</sup>. Clinical manifestations may include hypophosphatemia, renal potassium wasting, metabolic acidosis with a normal ion gap, and, rarely, polyuria due to nephrogenic diabetes insipidus.</li> <li>Refer to UpToDate topics on ifosfamide nephrotoxicity.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Neurologic toxicity</strong></td> <td colspan="3"> <ul> <li><strong>Cisplatin:</strong> Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment.</li> <li>Refer to UpToDate topics on neurologic complications of platinum-based chemotherapy.</li> <li><strong>Ifosfamide:</strong> CNS toxicities can be severe and result in encephalopathy and death. CNS side effects may be especially problematic for those over age 60. Discontinue ifosfamide treatment for encephalopathy.</li> <li>Refer to UpToDate topics on overview of neurologic complications of non-platinum cancer chemotherapy.</li> <li><strong>Vinblastine:</strong> Care must be taken to avoid constipation in patients receiving vincristine. For severe paresthesias and/or constipation, the dose of vinblastine should be reduced by <span style="white-space: nowrap;">50%.<sup>[1]</sup></span> Vinblastine should be discontinued permanently if an adynamic ileus occurs.</li> <li>Refer to UpToDate topics on overview of neurologic complications of non-platinum cancer chemotherapy.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">NS: normal saline; IV: intravenous; D5W: 5% dextrose in water; RBC: red blood cell; CNS: central nervous system; CBC: complete blood count; WBC: white blood cell; BUN: blood urea nitrogen; CrCl: creatinine clearance.<br/>
* In the original protocol, ifosfamide and vinblastine doses were reduced by 25% in patients with previous abdominal or chest <font style="white-space: nowrap;">radiotherapy.<sup>[1]</sup></font><br/>
¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br/>
Δ Vinblastine should not be diluted in large volumes of diluent (ie, &gt;100 mL) or given IV for prolonged periods (ie, &gt;30 minutes), since this may result in vein irritation and risk of extravasation.<br/>
◊ Alternatively, may dilute in 2 L dextrose 5% and sodium chloride 0.45% or dextrose 5% and sodium chloride 0.3% containing 37.5 g of mannitol, and infuse over a 6- to 8-hour <font style="white-space: nowrap;">period.<sup>[5]</sup></font><br/>
§ Due to a longer half-life of ifosfamide and associated metabolites, some references recommend continuation of mesna for 12 to 24 hours beyond completion of ifosfamide to reduce the risk of hemorrhagic cystitis. If necessary, oral mesna may be used at a dose twice that of IV mesna.<br/>
¥ The original protocol used a daily mesna dose of 400 mg/m<sup>2</sup> IV bolus prior to ifosfamide, followed by 1200 mg/m<sup>2</sup> per day continuous IV <font style="white-space: nowrap;">infusion.<sup>[1,2]</sup></font> Alternative administration schedules also exist and may vary by institution, including the use of continuous infusion mesna.</div><div class="graphic_reference">References:
<ol>
<li>Loehrer PJ Sr, et al. Ann Intern Med 1988; 109:504.</li>
<li>Loehrer PJ Sr, et al. J Clin Oncol 1998; 16:2500.</li>
<li>Morales ASR, et al. J Oncol Pharm Practice 2020; supplements 1 and 2.</li>
<li>MESNA injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed September 9, 2021).</li>
<li>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on September 9, 2021).</li>
<li>Ifosfamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed September 9, 2021).</li>
<li>Vinblastine injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on September 9, 2021).</li>
</ol></div><div id="graphicVersion">Graphic 134380 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
